Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

Clinical trial NCT06970782 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06970782
Sponsor: Avistone Biotechnology Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-Small-Cell Lung Cancer

Start date: 2025-05-15
Primary completion: 2027-12-31
Enrollment: 278

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.